Varlilumab ELISA Kit|瓦利鲁单抗ELISA检测试剂盒(靶标：瓦利鲁单抗酶联免疫检测试剂盒)
- 货号：RB9TDB796018
- 价格：面议
- 点击：216
产品介绍
产品参数
| 应用 | ELISA |
|---|---|
| 检测方法 | Colorimetric |
| 灵敏度 | 0.156 μg/ml |
| 检测范围 | 0.31-5 μg/mL |
| 回收率 | 80-120% |
| 样本类型 | Plasma, Serum |
| 检测类型 | Quantitative |
| 稳定性和储存 | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 20% prior to the expiration date under appropriate storage condition. |
| 运输条件 | 2-8 ℃ |
| 登录号 | P26842 |
| 背景信息 | Varlilumab (CDX-1127), a human IgG1κ monoclonal antibody, targets CD27 receptor through reacting with the ligand binding site of CD27. CD27 is a member of the tumor necrosis factor receptor superfamily and expressed on unstimulated T lymphocytes, serving as a potent costimulatory molecule. It has been found that CD27 induces a series of T-cell reactions including T-cell activation, proliferation, survival, and maturation of effector capacity and T-cell memory together with its ligand CD70, which is transiently expressed on antigen-presenting cells. Besides, the interaction of CD27 and CD70 also stimulate B-cell proliferation, generation of plasma cells, production of immunoglobulin and B-cell memory, and induction of the cytolytic activity of natural killer (NK) cells. Moreover, CD27 is considered to function on tumor expansion and activation as it also expressed by regulatory T cells (Tregs), a cell that is associated with the suppression of antitumor immunity. The drug, developed by Celldex Therapeutics, is designed for immunotherapy for patients with solid tumors and hematologic malignancies. Varlilumab is currently conducted with two trails. One is the phase 1B clinical trial for advanced breast or ovarian cancer in combination with ONT-10. Another is the phase 1/2 trial for advanced refractory solid tumors together with anti-PD-1 nivolumab. |
| 别名 | 1F5, CDX-1127, 1393344-72-3 |
| 备注 | For Research Use Only. |
相关产品:
